Retatrutide, from Soma Pharmaceuticals , represents a significant breakthrough in metabolic management . This dual-action compound combines hormonal signaling properties with GIP pathway stimulation , indicating impressive potential in clinical studies for body improvement. Experts believe the drug is expected to represent a new option for patients